Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Consultation record

Submissions accepted — page 6

The submission is accepted and the draft is amended as proposed. The amendment is recorded in the amendment log of the document it changed and is traceable to the numbered submission.

Submissions

735 documents · page 6 of 25

Table 1. Submissions with this disposition, on this page.

ReferenceConsultationRespondentPoint raised
DRAFT-CORRECTIONS-/015Draft corrections and versioning policyStellan Cholmondeley-AdeThe search date is not on the face of the document
DRAFT-CORRECTIONS-/016Draft corrections and versioning policyDr Jozef Brandvold-AchterbergDisagreement within the assessment committee is not visible
DRAFT-CORRECTIONS-/018Draft corrections and versioning policyDr Jerome PetrossianNo period is stated within which a submission will be answered
DRAFT-STABILITY-ST/001Draft standard: freeze–thaw and in-use stability assessment of…Dr Vasilisa ImmelmannNothing requires the report to state who performed the determination
DRAFT-STABILITY-ST/004Draft standard: freeze–thaw and in-use stability assessment of…Professor Bartolomeu Nkosi-LindegaardA conformance claim is not defined and will be made loosely
DRAFT-STABILITY-ST/008Draft standard: freeze–thaw and in-use stability assessment of…Dr Eamon ImmelmannThe scope does not say which materials the standard excludes
DRAFT-STABILITY-ST/010Draft standard: freeze–thaw and in-use stability assessment of…Dr Evander Whitmarsh-ObiThe reporting threshold is not tied to a demonstrated limit of quantitation
DRAFT-STABILITY-ST/012Draft standard: freeze–thaw and in-use stability assessment of…Dr Anselm Thorsby-NakamuraThe draft prescribes a procedure where it should state performance
DRAFT-STABILITY-ST/013Draft standard: freeze–thaw and in-use stability assessment of…Dr Theodora TrelawneyThe limitations section states what the method cannot do but not what a reader will wrongly conclude
DRAFT-STABILITY-ST/015Draft standard: freeze–thaw and in-use stability assessment of…Dr Fitzwilliam Danquah-ÖbergThe light source is not specified and results will not be comparable
DRAFT-INDICATION-S/001Draft indication set and anchor outcomesQuentin Whitmarsh-ObiThe front-matter summary describes the finding without stating it
DRAFT-INDICATION-S/002Draft indication set and anchor outcomesDr Melisande Kirkpatrick-OlaFour dates are given and their relation is not explained
DRAFT-INDICATION-S/003Draft indication set and anchor outcomesDr Frideswide NordhagenA printed copy loses the information that makes it checkable
DRAFT-INDICATION-S/005Draft indication set and anchor outcomesDr Hyacinth Drakeford-AmadiA printed copy loses the document identifier
DRAFT-INDICATION-S/006Draft indication set and anchor outcomesDr Vasilisa ImmelmannThe identifier encodes the document type, which is a property that can change
DRAFT-INDICATION-S/009Draft indication set and anchor outcomesEamon Sandringham-AduThe registry is published only as pages and not in a form that can be processed
DRAFT-INDICATION-S/010Draft indication set and anchor outcomesIvo MountstephenThe same quantity is presented differently in two series
DRAFT-INDICATION-S/011Draft indication set and anchor outcomesDr Fenella Steenkamp-FerreiraThe default ordering of a comparison table carries an implication
DRAFT-INDICATION-S/012Draft indication set and anchor outcomesDr Yusuf Whitmarsh-ObiThe index shows ratings without the reasons behind them
DRAFT-INDICATION-S/013Draft indication set and anchor outcomesDr Marisol Dunmore-EkpoA section with nothing in it is emitted with a heading and a sentence saying so
DRAFT-MASH-SYNTHES/001Draft synthesis: incretin receptor agonists for metabolic…Dr Ludmila TollemacheAn indirect comparison is presented without an assessment of transitivity
DRAFT-MASH-SYNTHES/002Draft synthesis: incretin receptor agonists for metabolic…Dr Constança Glendinning-UcheThe same concept is given three different names in one document
DRAFT-MASH-SYNTHES/003Draft synthesis: incretin receptor agonists for metabolic…Thaddeus Isaksen-BalogunIntention-to-treat and efficacy-estimand results are combined without distinction
DRAFT-MASH-SYNTHES/004Draft synthesis: incretin receptor agonists for metabolic…Dr Vittoria QuintanilhaRisk-of-bias judgements are reported as an overall rating without the domains
DRAFT-MASH-SYNTHES/007Draft synthesis: incretin receptor agonists for metabolic…Dr Ndidi Ravensworth-IlungaOne trial appears to be included twice under two publications
DRAFT-MASH-SYNTHES/008Draft synthesis: incretin receptor agonists for metabolic…Dr Zdenka XimenesEfficacy outcomes are rated for certainty and harms are not
DRAFT-MASH-SYNTHES/010Draft synthesis: incretin receptor agonists for metabolic…Eamon Sandringham-AduThe search date is not on the face of the document
DRAFT-ADOLESCENT-S/002Draft synthesis: incretin receptor agonists in adolescentsDr Yaa KettlewellThe timepoint at which each outcome was extracted was chosen after the data were seen
DRAFT-ADOLESCENT-S/003Draft synthesis: incretin receptor agonists in adolescentsDr Ndidi Ravensworth-IlungaRegistered trials that never reported are not counted anywhere in the review
DRAFT-ADOLESCENT-S/004Draft synthesis: incretin receptor agonists in adolescentsDr Vittoria QuintanilhaThe conclusion is stated more strongly than the certainty rating supports

page 6 of 25

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.